IDH2 and acute myeloid leukemia: New therapeutic options, including small inhibitors of somatic mutations commonly found in AML, such as FLT3 or isocitrate dehydrogenase (IDH) inhibitors, have been approved recently for relapsing or refractory (RR) patients.